• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Seres Therapeutics Inc (NQ: MCRB )

    0.8119 +0.0045 (+0.56%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Seres Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Seres Therapeutics to Host Third Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on November 10, 2021
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Presents Late-Breaking Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at IDWeek2021
    From Seres Therapeutics, Inc.
    Via Business Wire
    The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
    Via Benzinga
    Exposures Product Safety
    The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
    Via Benzinga
    Seres Therapeutics Presents Data Supporting its Microbiome Pipeline at IDWeek 2021, Including Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection
    From Seres Therapeutics, Inc.
    Via Business Wire
    53 Biggest Movers From Yesterday
    Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share. PROCEPT BioRobotics Corporation... 
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    Analyst Ratings For Seres Therapeutics
    Within the last quarter, Seres Therapeutics (NASDAQ:MCRB)... 
    Via Benzinga
    Why Seres Therapeutics Stock Is Soaring Today
    The company completed its target enrollment in a pivotal clinical study. 
    Via The Motley Fool
    Why Seres Therapeutics Shares Are Trading Higher Today
    Seres Therapeutics (NASDAQ:MCRB) shares are trading higher after the company achieved enrollment of 300 subjects in its Phase 3 ECOSPOR IV study of SER-109. Seres... 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 211.66% to $22.04 during Wednesday's regular session. The market value of their outstanding shares... 
    Via Benzinga
    Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection
    From Seres Therapeutics, Inc.
    Via Business Wire
    The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
    Via Benzinga
    Exposures COVID-19
    Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences
    From Seres Therapeutics, Inc.
    Via Business Wire
    The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
    Via Benzinga
    Exposures COVID-19
    Stocks That Hit 52-Week Lows On Friday
    Before 10 a.m. ET on Friday, 29 stocks hit new 52-week lows. Significant Points: Campbell Soup (NYSE:CPB) was the biggest company by market cap to set a new 52-week low.... 
    Via Benzinga
    The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Wednesday
    On Wednesday morning, 67 companies achieved new lows for the year. Areas of Significance: Grifols (NASDAQ:GRFS) was the largest firm by market cap to set a new 52-... 
    Via Benzinga
    The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
    Via Benzinga
    Exposures COVID-19
    Stocks That Hit 52-Week Lows On Monday
    On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap to set a new 52-week low was Koninklijke Philips (NYSE... 
    Via Benzinga
    The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
    Via Benzinga
    Exposures Product Safety
    The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
    Via Benzinga
    Exposures Product Safety
    Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
    From Seres Therapeutics, Inc.
    Via Business Wire
    The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
    Via Benzinga
    Recap: Seres Therapeutics Q2 Earnings
    Shares of Seres Therapeutics (NASDAQ:MCRB) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 89.29... 
    Via Benzinga
    Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021
    From Seres Therapeutics, Inc.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021
    Upgrades Craig-Hallum upgraded the previous rating for Lindblad Expeditions Holdings Inc (NAS... 
    Via Benzinga
    The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
    Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
    Via Benzinga
    Exposures Product Safety
    10 Biggest Price Target Changes For Friday
    Keybanc raised the price target on Twitter, Inc. (NYSE: TWTR) from $77 to $81. Twitter shares rose 6.4% to $74.00 in pre-market trading. Baird boosted the price target for... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.